Published in Pediatr Blood Cancer on August 01, 2009
Randomized Trial of Suicide Gene Therapy and Prostate Cancer (ReCAP) | NCT00583492
Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 15.30
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 10.40
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med (2006) 9.68
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 6.46
In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science (1992) 5.47
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. J Pediatr (2005) 1.81
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell (2008) 1.70
Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol (2000) 1.70
Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. Eur J Cancer (2004) 1.60
Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst (2007) 1.52
A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther (2001) 1.51
Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol (2005) 1.46
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther (2001) 1.42
Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res (2007) 1.38
Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res (2005) 1.19
Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Ther (1998) 1.14
Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther (2007) 1.12
Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology (2009) 1.11
Hepatoblastoma and low birth weight: a trend or chance observation? Med Pediatr Oncol (2002) 1.09
Outcome of hepatoblastoma treated with the JPLT-1 (Japanese Study Group for Pediatric Liver Tumor) Protocol-1: A report from the Japanese Study Group for Pediatric Liver Tumor. J Pediatr Surg (2002) 1.05
Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther (2006) 0.98
[Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99]. Klin Padiatr (2003) 0.98
Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res (2007) 0.94
Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol (2008) 0.94
Gene therapy for the treatment of recurrent pediatric malignant astrocytomas with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Hum Gene Ther (1994) 0.92
A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res (2003) 0.91
Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol (2009) 0.90
Percutaneous radiofrequency ablation for treatment of hepatoblastoma recurrence. Pediatr Radiol (2008) 0.90
Preoperative transcatheter selective arterial chemoembolization in treatment of unresectable hepatoblastoma in infants and children. Cardiovasc Intervent Radiol (2008) 0.84
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther (2007) 0.84
Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer (2009) 0.78
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. Cancer Res (2009) 1.47
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther (2008) 1.44
Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One (2009) 1.40
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. J Pediatr Surg (2005) 1.39
Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A. Cancer Res (2006) 1.32
Cancer-selective targeting and cytotoxicity by liposomal-coupled lysosomal saposin C protein. Clin Cancer Res (2009) 1.26
Tissue inhibitor of metalloproteinase-3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res (2008) 1.24
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer (2009) 1.19
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model. Mol Ther (2007) 1.15
Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. Mol Ther (2010) 1.14
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 1.12
Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther (2005) 1.11
Saposin C coupled lipid nanovesicles enable cancer-selective optical and magnetic resonance imaging. Mol Imaging Biol (2011) 1.08
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress. Curr Pharm Biotechnol (2012) 1.03
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatr Blood Cancer (2011) 1.02
Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer (2005) 1.01
Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer (2010) 0.99
A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells. Cancer Res (2013) 0.99
Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer (2006) 0.98
Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target. Clin Cancer Res (2012) 0.98
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy. Clin Cancer Res (2010) 0.97
Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. J Pediatr Hematol Oncol (2003) 0.96
Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol (2002) 0.94
Differing approaches to experimental therapeutics: are we a world apart? Mol Ther (2012) 0.89
Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol (2002) 0.87
Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol (2003) 0.87
Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatr Blood Cancer (2014) 0.86
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells. Mol Ther (2013) 0.83
Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer (2014) 0.83
EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model. J Surg Res (2011) 0.82
Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors. J Gene Med (2010) 0.82
Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression. PLoS One (2011) 0.80
Going back to class I: MHC and immunotherapies for childhood cancer. Pediatr Blood Cancer (2014) 0.80
In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1. Cancer Res (2012) 0.79
Improving patient care: the use of a digital teaching file to enhance clinicians' access to the intellectual capital of interdepartmental conferences. AJR Am J Roentgenol (2004) 0.78
Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J Pediatr Hematol Oncol (2002) 0.78
A lab-on-a-chip for rapid blood separation and quantification of hematocrit and serum analytes. Lab Chip (2011) 0.78
Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy. Pediatr Blood Cancer (2014) 0.78
Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. J Clin Invest (2015) 0.77
Adventitious mutations in clinical grade vectors: an issue to consider? Mol Ther (2006) 0.76
Emerging cancer-targeted therapies. Pediatr Clin North Am (2002) 0.75
A young girl with hemolytic anemia and elevated hemoglobin F. Pediatr Blood Cancer (2005) 0.75